Drug-to-market cost falls to under $2bn in five years

30-09-2019

Sarah Morgan

Drug-to-market cost falls to under $2bn in five years

sharafmaksumov / Shutterstock.com

Bringing a drug to market is costing companies under $2 billion for the first time in five years, according to a report from IP service provider Clarivate Analytics.


Clarivate Analytics, drugs, pharmaceuticals, market, pricing, R&D, research and development, drug approvals

LSIPR